Now showing items 1-2 of 2

    • Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer. 

      Puyang, X; Furman, C; Zheng, GZ; Wu, ZJ; Banka, D; Aithal, K; Agoulnik, S; Bolduc, DM; Buonamici, S; Caleb, B; Das, S; Eckley, S; Fekkes, P; Hao, M-H; Hart, A; Houtman, R; Irwin, S; Joshi, JJ; Karr, C; Kim, A; Kumar, N; Kumar, P; Kuznetsov, G; Lai, WG; Larsen, N; Mackenzie, C; Martin, L-A; Melchers, D; Moriarty, A; Nguyen, T-V; Norris, J; O'Shea, M; Pancholi, S; Prajapati, S; Rajagopalan, S; Reynolds, DJ; Rimkunas, V; Rioux, N; Ribas, R; Siu, A; Sivakumar, S; Subramanian, V; Thomas, M; Vaillancourt, FH; Wang, J; Wardell, S; Wick, MJ; Yao, S; Yu, L; Warmuth, M; Smith, PG; Zhu, P; Korpal, M (2018-09)
      Mutations in estrogen receptor alpha (ERα) that confer resistance to existing classes of endocrine therapies are detected in up to 30% of patients who have relapsed during endocrine treatments. Because a significant ...
    • Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. 

      Cuzick, J; Sestak, I; Forbes, JF; Dowsett, M; Cawthorn, S; Mansel, RE; Loibl, S; Bonanni, B; Evans, DG; Howell, A; IBIS-II investigators (2020-01)
      BACKGROUND:Two large clinical trials have shown a reduced rate of breast cancer development in high-risk women in the initial 5 years of follow-up after use of aromatase inhibitors (MAP.3 and International Breast Cancer ...